ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProQR ( (PRQR) ) just unveiled an update.
On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting progress on lead candidate AX-0810 for cholestatic diseases, which is in an ongoing Phase 1 multiple-dose study in healthy volunteers with encouraging initial safety and pharmacokinetics. The company expects target engagement data in the first half of 2026 and is preparing to add a primary sclerosing cholangitis patient cohort, underscoring a push to translate its RNA editing technology into clinical proof of concept.
ProQR also strengthened its Axiomer pipeline by selecting development candidates AX-2402 for Rett syndrome and AX-2911 for genetically defined MASH, backed by robust preclinical data and external funding for the Rett program, while continuing to generate collaboration milestones from Eli Lilly. The company ended 2025 with €92.4 million in cash and cash equivalents, a higher net loss driven by increased R&D investment, and projected a cash runway into mid-2027 alongside planned board changes aimed at supporting its evolution as a clinical-stage RNA editing player.
The most recent analyst rating on (PRQR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s significant financial challenges, particularly in profitability and cash flow, are the most critical factors. Technical indicators suggest bearish momentum, and the valuation reflects ongoing losses. These factors collectively contribute to a lower overall stock score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on RNA-based medicines, developing transformative therapies using its proprietary Axiomer RNA editing platform. The company targets both rare and prevalent diseases with high unmet need, including cholestatic liver disorders, Rett syndrome, and metabolic dysfunction-associated steatohepatitis (MASH), and also advances partnered programs through a strategic collaboration with Eli Lilly.
Average Trading Volume: 440,106
Technical Sentiment Signal: Sell
Current Market Cap: $190.7M
For detailed information about PRQR stock, go to TipRanks’ Stock Analysis page.
